{"hands_on_practices": [{"introduction": "The diagnosis of rheumatoid arthritis (RA) relies on integrating a diverse set of findings, from joint examinations to serological tests. To standardize this process, the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria were developed. This exercise [@problem_id:4447055] provides a hands-on opportunity to apply this essential classification tool, demonstrating how different pathological domains contribute additively to a definitive classification score.", "problem": "In the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification framework for rheumatoid arthritis (RA), the disease is classified using a weighted, domain-based scoring system that aggregates evidence from joint involvement, serology, acute-phase reactants, and symptom duration. This approach is grounded in the principle that independent pathological domains contribute additive evidence toward classification. The foundational facts for this derivation are: (i) independent domains are aggregated linearly; (ii) each domain contributes a fixed number of points determined by validated criteria; and (iii) the total score is the sum of domain contributions.\n\nConsider a patient in whom the following domain-level findings have been established by standard clinical and laboratory methods:\n- Joint involvement: involvement of 10 small joints, qualifying for the small-joint category.\n- Serology: high-positive anti-cyclic citrullinated peptide (anti-CCP) antibody, defined per assay as above the high-positive threshold.\n- Acute-phase reactants: abnormal C-reactive protein (CRP).\n- Duration: symptom duration greater than 6 weeks.\n\nUse the following empirically validated point allocations, which reflect the weighting of evidence in each domain:\n- Small-joint involvement at the level described above contributes 5 points.\n- High-positive serology (anti-CCP or rheumatoid factor) contributes 3 points.\n- Abnormal acute-phase reactants (CRP or erythrocyte sedimentation rate) contribute 1 point.\n- Symptom duration greater than 6 weeks contributes 1 point.\n\nStarting from the principle that the total classification score is an additive aggregation of domain-specific contributions, construct a symbolic scoring function that maps these domain indicators to a total score, and then evaluate this function for the patient described. Express the final score as an exact number. No rounding is required, and no units are to be used in the final answer.", "solution": "The problem statement is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\nThe givens are extracted verbatim from the problem statement:\n- **Principle (i):** \"independent domains are aggregated linearly\"\n- **Principle (ii):** \"each domain contributes a fixed number of points determined by validated criteria\"\n- **Principle (iii):** \"the total score is the sum of domain contributions\"\n- **Patient Finding (Joints):** \"involvement of 10 small joints, qualifying for the small-joint category.\"\n- **Patient Finding (Serology):** \"high-positive anti-cyclic citrullinated peptide (anti-CCP) antibody, defined per assay as above the high-positive threshold.\"\n- **Patient Finding (Reactants):** \"abnormal C-reactive protein (CRP).\"\n- **Patient Finding (Duration):** \"symptom duration greater than 6 weeks.\"\n- **Point Allocation (Joints):** \"Small-joint involvement at the level described above contributes 5 points.\"\n- **Point Allocation (Serology):** \"High-positive serology (anti-CCP or rheumatoid factor) contributes 3 points.\"\n- **Point Allocation (Reactants):** \"Abnormal acute-phase reactants (CRP or erythrocyte sedimentation rate) contribute 1 point.\"\n- **Point Allocation (Duration):** \"Symptom duration greater than 6 weeks contributes 1 point.\"\n- **Task:** \"construct a symbolic scoring function that maps these domain indicators to a total score, and then evaluate this function for the patient described.\"\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is based on the 2010 ACR/EULAR classification criteria for rheumatoid arthritis, a standard and widely accepted clinical tool in rheumatology. The principles of additive scoring and the specific point values for the described clinical findings are factually correct and derived directly from the published guidelines. The problem is firmly grounded in established medical science.\n2.  **Well-Posed:** The problem provides a complete set of patient findings and a corresponding, unambiguous scoring system. The instruction to sum the points leads to a unique and meaningful numerical solution.\n3.  **Objective:** The problem uses precise, objective clinical terminology and provides explicit numerical values for scoring. It is free of ambiguity, subjectivity, or opinion.\n\n### Step 3: Verdict and Action\nThe problem statement is scientifically sound, well-posed, objective, and self-contained. It contains no contradictions or missing information. Therefore, the problem is deemed **valid**. A solution will be constructed.\n\nThe problem requires the construction of a symbolic scoring function and its evaluation for a specific case. The fundamental principle stated is that the total classification score is an additive aggregation of contributions from independent domains.\n\nLet the total score be denoted by the variable $S$. The four domains are joint involvement, serology, acute-phase reactants, and duration. We can define symbolic variables representing the points contributed by each domain:\n- $P_J$: Points for joint involvement.\n- $P_S$: Points for serology.\n- $P_A$: Points for acute-phase reactants.\n- $P_D$: Points for symptom duration.\n\nBased on the principle of linear, additive aggregation, the symbolic scoring function $S$ is the sum of the points from each domain. The function maps the set of points from the individual domains to a total score:\n$$S(P_J, P_S, P_A, P_D) = P_J + P_S + P_A + P_D$$\n\nNext, we must evaluate this function for the patient described by substituting the specific point values corresponding to the patient's clinical findings. The problem provides these values:\n\n1.  **Joint Involvement:** The patient has involvement of 10 small joints. According to the provided criteria, this contributes 5 points.\n    $$P_J = 5$$\n2.  **Serology:** The patient is high-positive for anti-CCP antibodies. This contributes 3 points.\n    $$P_S = 3$$\n3.  **Acute-Phase Reactants:** The patient has an abnormal CRP. This contributes 1 point.\n    $$P_A = 1$$\n4.  **Duration:** The symptom duration is greater than 6 weeks. This contributes 1 point.\n    $$P_D = 1$$\n\nSubstituting these numerical values into the symbolic scoring function yields the total score $S$ for this patient:\n$$S = 5 + 3 + 1 + 1$$\nPerforming the summation:\n$$S = 10$$\nThe total score for this patient, according to the 2010 ACR/EULAR criteria as specified, is 10. Within the context of the full classification system, a score of 6 or greater is classified as definite rheumatoid arthritis. The calculated score of 10 is consistent with a definitive classification.\nThe final answer is the exact numerical value of the total score.", "answer": "$$\\boxed{10}$$", "id": "4447055"}, {"introduction": "Once RA is diagnosed, the focus shifts to managing the disease and preventing long-term damage. The \"treat-to-target\" approach, a cornerstone of modern rheumatology, requires objective, quantitative monitoring of disease activity. This practice [@problem_id:4447069] will guide you through the calculation of the Disease Activity Score in 28 joints with C-reactive protein ($DAS28\\text{-CRP}$), a widely used composite index that translates multiple clinical variables into a single, actionable score to guide therapy.", "problem": "A patient with established rheumatoid arthritis is assessed using the standard components of the Disease Activity Score using 28-joint counts with C-reactive protein ($DAS28\\text{-CRP}$): the 28-joint tender joint count ($TJC_{28}$), the 28-joint swollen joint count ($SJC_{28}$), the C-reactive protein concentration ($CRP$) measured in $\\mathrm{mg/L}$, and the patient’s global health ($GH$) recorded on a $0$ to $100$ millimeter visual analogue scale. The widely validated composite scoring model for $DAS28\\text{-CRP}$ is based on a multiple linear combination of transformed predictors and an intercept, with empirically determined coefficients from regression analyses in rheumatoid arthritis cohorts:\n- a coefficient of $0.56$ multiplies $\\sqrt{TJC_{28}}$,\n- a coefficient of $0.28$ multiplies $\\sqrt{SJC_{28}}$,\n- a coefficient of $0.36$ multiplies $\\ln(CRP+1)$ where $\\ln$ denotes the natural logarithm and $CRP$ is in $\\mathrm{mg/L}$,\n- a coefficient of $0.014$ multiplies $GH$ (in millimeters on the $0$–$100$ scale),\n- and a constant intercept of $0.96$ is added.\n\nFor a patient with $TJC_{28} = 6$, $SJC_{28} = 4$, $CRP = 20 \\text{ mg/L}$, and $GH = 50 \\text{ mm}$, compute the $DAS28\\text{-CRP}$ score using this model. Round your final answer to four significant figures. The score is dimensionless; report only the numerical value.", "solution": "The problem is subjected to validation and is deemed valid. It is scientifically grounded in established clinical rheumatology, specifically the use of the Disease Activity Score using 28-joint counts with C-reactive protein ($DAS28\\text{-CRP}$) for monitoring rheumatoid arthritis. The problem is well-posed, providing a precise formula and all necessary input values for a direct and unambiguous calculation.\n\nThe formula for the $DAS28\\text{-CRP}$ score is provided as a linear combination of transformed clinical variables and a constant intercept:\n$$DAS28\\text{-CRP} = (0.56 \\times \\sqrt{TJC_{28}}) + (0.28 \\times \\sqrt{SJC_{28}}) + (0.36 \\times \\ln(CRP+1)) + (0.014 \\times GH) + 0.96$$\nwhere:\n- $TJC_{28}$ is the tender joint count (out of $28$).\n- $SJC_{28}$ is the swollen joint count (out of $28$).\n- $CRP$ is the C-reactive protein concentration in $\\mathrm{mg/L}$.\n- $GH$ is the patient's global health assessment on a $0$ to $100$ mm visual analogue scale.\n\nThe specific values provided for the patient are:\n- $TJC_{28} = 6$\n- $SJC_{28} = 4$\n- $CRP = 20 \\text{ mg/L}$\n- $GH = 50 \\text{ mm}$\n\nWe substitute these values into the $DAS28\\text{-CRP}$ formula:\n$$DAS28\\text{-CRP} = (0.56 \\times \\sqrt{6}) + (0.28 \\times \\sqrt{4}) + (0.36 \\times \\ln(20+1)) + (0.014 \\times 50) + 0.96$$\n\nWe proceed to calculate each term individually before summing them.\n\nThe first term is $0.56 \\times \\sqrt{6}$.\n$$0.56 \\times \\sqrt{6} \\approx 0.56 \\times 2.44948974 \\approx 1.37171425$$\n\nThe second term is $0.28 \\times \\sqrt{4}$.\n$$0.28 \\times \\sqrt{4} = 0.28 \\times 2 = 0.56$$\n\nThe third term is $0.36 \\times \\ln(20+1) = 0.36 \\times \\ln(21)$. The natural logarithm, $\\ln(21)$, is approximately $3.04452244$.\n$$0.36 \\times \\ln(21) \\approx 0.36 \\times 3.04452244 \\approx 1.09602808$$\n\nThe fourth term is $0.014 \\times 50$.\n$$0.014 \\times 50 = 0.7$$\n\nThe constant intercept is $0.96$.\n\nNow, we sum these values to compute the total $DAS28\\text{-CRP}$ score:\n$$DAS28\\text{-CRP} \\approx 1.37171425 + 0.56 + 1.09602808 + 0.7 + 0.96$$\n$$DAS28\\text{-CRP} \\approx 4.68774233$$\n\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is approximately $4.6877$. The fifth significant digit is $7$, which is greater than or equal to $5$, so we round up the fourth significant digit.\n$$4.6877... \\rightarrow 4.688$$\n\nThus, the $DAS28\\text{-CRP}$ score for this patient, rounded to four significant figures, is $4.688$.", "answer": "$$\\boxed{4.688}$$", "id": "4447069"}, {"introduction": "The true challenge of clinical medicine lies in synthesizing data to make patient-centered decisions. This final practice [@problem_id:4447046] presents a realistic clinical scenario where you must apply the \"treat-to-target\" strategy in practice. By first assessing the patient's disease activity state (using a score like the $DAS28\\text{-CRP}$ from [@problem_id:4447069]), you will then navigate the complexities of escalating therapy, balancing the need for efficacy against crucial safety considerations and patient comorbidities.", "problem": "A 45-year-old woman has seropositive rheumatoid arthritis characterized by positive rheumatoid factor and anti-cyclic citrullinated peptide antibodies, with radiographic erosions in the metacarpophalangeal joints. She has been managed using a treat-to-target strategy. Methotrexate has been optimized to 25 mg weekly for 12 weeks with folic acid supplementation; adherence has been verified by pharmacy records and serum methotrexate polyglutamate measurement. She continues to report morning stiffness of approximately 90 minutes and functional limitation. On examination, the tender joint count in 28 joints is 8, the swollen joint count in 28 joints is 6. Laboratory testing shows C-reactive protein (CRP) 12 mg/L, alanine aminotransferase (ALT) 65 U/L (upper limit of normal 40 U/L), and a negative interferon gamma release assay for tuberculosis. Patient global assessment on a 0 to 100 mm visual analog scale (VAS) is 60 mm. She has a history of an unprovoked deep vein thrombosis 1 year ago, now off anticoagulation, and no chronic infections. Vaccinations are up to date.\n\nUse fundamental pathological and clinical principles pertinent to rheumatoid arthritis: persistent synovial inflammation is driven by proinflammatory cytokines such as Tumor Necrosis Factor (TNF) and Interleukin-6 (IL-6), which correlate with composite disease activity indices such as the Disease Activity Score in 28 joints (DAS28). In treat-to-target, the target is remission or low disease activity, typically defined by DAS28 categories where values $<2.6$ indicate remission, $\\leq 3.2$ indicate low disease activity, $>3.2$ to $\\leq 5.1$ indicate moderate disease activity, and $>5.1$ indicate high disease activity. If, after an adequate trial and optimization of a conventional synthetic Disease Modifying Anti-Rheumatic Drug (DMARD) such as methotrexate, DAS28 remains above $3.2$, therapy should be escalated by modulating key cytokine pathways or combining DMARDs, while accounting for safety constraints.\n\nWhich of the following is the most appropriate next step consistent with a treat-to-target strategy for this patient, given the data and comorbidities?\n\nA. Add sulfasalazine and hydroxychloroquine to methotrexate (triple conventional synthetic DMARD therapy), without glucocorticoid bridging, and plan reassessment in 3 months\n\nB. Add a Tumor Necrosis Factor inhibitor (for example, adalimumab) to methotrexate after confirming negative tuberculosis screening, and plan reassessment in 3 months\n\nC. Increase methotrexate to 35 mg weekly despite elevated alanine aminotransferase, and reassess in 6 months\n\nD. Start long-term prednisone 10 mg daily as maintenance therapy while continuing methotrexate, deferring other DMARD changes\n\nE. Switch to leflunomide in combination with methotrexate despite current alanine aminotransferase elevation, and reassess in 6 months\n\nF. Initiate a Janus Kinase (JAK) inhibitor (for example, tofacitinib) in view of inadequate response to methotrexate, despite a prior unprovoked deep vein thrombosis", "solution": "The problem statement will be validated before proceeding to a solution.\n\n### Step 1: Extract Givens\n- **Patient Demographics**: A 45-year-old woman.\n- **Diagnosis**: Seropositive rheumatoid arthritis (RA).\n- **Serology**: Positive rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.\n- **Radiographic Findings**: Erosions in the metacarpophalangeal (MCP) joints.\n- **Treatment History**:\n    - Managed with a treat-to-target strategy.\n    - Methotrexate (MTX) optimized to 25 mg weekly for 12 weeks.\n    - Folic acid supplementation provided.\n    - Adherence verified by pharmacy records and serum methotrexate polyglutamate measurement.\n- **Clinical Symptoms**:\n    - Morning stiffness of approximately 90 minutes.\n    - Functional limitation.\n- **Physical Examination**:\n    - Tender joint count in 28 joints (TJC28) = 8.\n    - Swollen joint count in 28 joints (SJC28) = 6.\n- **Laboratory Data**:\n    - C-reactive protein (CRP) = 12 mg/L.\n    - Alanine aminotransferase (ALT) = 65 U/L (upper limit of normal 40 U/L).\n    - Negative interferon gamma release assay (IGRA) for tuberculosis.\n- **Patient-Reported Outcome**: Patient global assessment (GH) on a 0 to 100 mm visual analog scale (VAS) = 60 mm.\n- **Comorbidities/History**:\n    - History of an unprovoked deep vein thrombosis (DVT) 1 year ago, now off anticoagulation.\n    - No chronic infections.\n- **Vaccination Status**: Up to date.\n- **Fundamental Principles Provided**:\n    - RA pathophysiology involves proinflammatory cytokines like Tumor Necrosis Factor (TNF) and Interleukin-6 (IL-6).\n    - Disease activity is measured by composite indices like the Disease Activity Score in 28 joints (DAS28).\n    - Treat-to-target aims for remission (DAS28 $< 2.6$) or low disease activity (DAS28 $\\leq 3.2$).\n    - DAS28 categories: moderate ($>3.2$ to $\\leq 5.1$), high ($>5.1$).\n    - Inadequate response to an optimized conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) like methotrexate (defined as DAS28 $> 3.2$) warrants therapy escalation.\n    - Escalation involves modulating cytokine pathways or combining DMARDs, accounting for safety constraints.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated for validity.\n\n- **Scientifically Grounded**: Yes. The case presentation, terminology (seropositive RA, treat-to-target, DAS28), therapeutic agents (methotrexate, TNF inhibitors, JAK inhibitors), and associated risks (hepatotoxicity, TB reactivation, thrombosis) are all standard and factual within the field of rheumatology. The fundamental principles provided are accurate summaries of current clinical practice guidelines.\n- **Well-Posed**: Yes. The problem presents a detailed clinical scenario and asks for the most appropriate next step in management. The provided data are sufficient to make a reasoned clinical decision based on established principles. A unique, optimal solution can be derived.\n- **Objective**: Yes. The problem is described using objective clinical language and quantitative data (joint counts, lab values). There are no subjective or opinion-based statements in the problem setup.\n- **No Flaws Identified**: The problem does not violate any of the specified invalidity criteria. It is scientifically sound, well-posed, objective, complete, and realistic.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be derived.\n\n### Derivation of Solution\nThe primary task is to determine the most appropriate next therapeutic step for this patient with rheumatoid arthritis based on a treat-to-target strategy, considering her disease activity, prior treatment, and comorbidities.\n\n**1. Assessment of Disease Activity**\nFirst, we must quantify the patient's current disease activity using the provided data and the Disease Activity Score in 28 joints using CRP (DAS28-CRP). The formula is:\n$$ \\text{DAS28-CRP} = 0.56 \\cdot \\sqrt{TJC_{28}} + 0.28 \\cdot \\sqrt{SJC_{28}} + 0.36 \\cdot \\ln(\\text{CRP} + 1) + 0.014 \\cdot \\text{GH} + 0.96 $$\nUsing the given values:\n- TJC28 = 8\n- SJC28 = 6\n- CRP = 12 mg/L\n- GH = 60 mm\n\n$$ \\text{DAS28-CRP} = 0.56 \\cdot \\sqrt{8} + 0.28 \\cdot \\sqrt{6} + 0.36 \\cdot \\ln(12 + 1) + 0.014 \\cdot 60 + 0.96 $$\n$$ \\text{DAS28-CRP} \\approx 0.56 \\cdot (2.828) + 0.28 \\cdot (2.449) + 0.36 \\cdot \\ln(13) + 0.84 + 0.96 $$\n$$ \\text{DAS28-CRP} \\approx 1.584 + 0.686 + 0.36 \\cdot (2.565) + 0.84 + 0.96 $$\n$$ \\text{DAS28-CRP} \\approx 1.584 + 0.686 + 0.923 + 0.84 + 0.96 \\approx 4.993 $$\nThe patient's DAS28-CRP score is approximately 4.99. According to the provided criteria, this indicates **moderate disease activity** ($3.2 < \\text{DAS28} \\leq 5.1$). The patient has failed to reach the target of low disease activity (DAS28 $\\leq 3.2$) despite an adequate trial of optimized methotrexate. Therefore, therapy escalation is required.\n\n**2. Evaluation of Comorbidities and Safety Constraints**\n- **Elevated ALT (65 U/L)**: This mild hepatotoxicity is likely related to methotrexate and advises against escalating the methotrexate dose or adding another known hepatotoxic agent.\n- **History of Unprovoked DVT**: This is a critical safety consideration. It represents a strong relative or absolute contraindication for medications known to increase thrombosis risk.\n\n### Option-by-Option Analysis\n\n**A. Add sulfasalazine and hydroxychloroquine to methotrexate (triple conventional synthetic DMARD therapy), without glucocorticoid bridging, and plan reassessment in 3 months**\nThis strategy, known as \"triple therapy,\" is a recognized and effective option for patients with an inadequate response to methotrexate. It does not carry the specific risks of thrombosis or tuberculosis reactivation associated with other agents. However, its efficacy may be less robust or slower in onset compared to biologic DMARDs. Given the patient's erosive disease, which is a poor prognostic factor, a more potent therapy might be preferred to halt structural damage. While a valid option, it may not be the *most* appropriate choice for this specific clinical picture with poor prognostic markers.\n**Verdict: Incorrect**. While a possible strategy, it is arguably less optimal than escalating to a biologic agent in a patient with poor prognostic factors like erosions.\n\n**B. Add a Tumor Necrosis Factor inhibitor (for example, adalimumab) to methotrexate after confirming negative tuberculosis screening, and plan reassessment in 3 months**\nThis is a standard and highly recommended escalation step for patients with moderate-to-high disease activity and poor prognostic factors (erosions, seropositivity) who have failed methotrexate monotherapy. The principle of modulating cytokine pathways (like TNF) is explicitly mentioned. The major safety concern for TNF inhibitors, reactivation of latent tuberculosis, has been appropriately assessed and is negative (negative IGRA). The mild elevation in ALT is a common finding and requires monitoring but is not an absolute contraindication to initiating a TNF inhibitor. This approach directly targets a key inflammatory pathway and has a high probability of achieving the treat-to-target goal and preventing further joint damage.\n**Verdict: Correct**. This option aligns perfectly with modern treatment guidelines for this patient profile, appropriately addresses safety pre-screening, and represents a potent strategy to control disease and prevent progression of erosions.\n\n**C. Increase methotrexate to 35 mg weekly despite elevated alanine aminotransferase, and reassess in 6 months**\nThis is inappropriate for two reasons. First, the patient is already on an optimized dose of 25 mg weekly, which is typically considered the maximum for balancing efficacy and toxicity. Second, and more importantly, increasing the dose in the setting of elevated ALT would significantly increase the risk of severe hepatotoxicity. The proposed reassessment interval of 6 months is also too long for a patient with active, inadequately controlled disease.\n**Verdict: Incorrect**. This action is unsafe and contrary to standard practice.\n\n**D. Start long-term prednisone 10 mg daily as maintenance therapy while continuing methotrexate, deferring other DMARD changes**\nLong-term use of glucocorticoids like prednisone at moderate doses ($> 7.5$ mg/day) is associated with significant and cumulative toxicity, including osteoporosis, diabetes, weight gain, cataracts, and increased cardiovascular risk. While short-term glucocorticoids can be used as \"bridging\" therapy to control symptoms while a new DMARD takes effect, they are not a suitable long-term maintenance strategy. This option fails to address the underlying disease progression with a disease-modifying agent.\n**Verdict: Incorrect**. This represents a poor long-term strategy due to unacceptable toxicity.\n\n**E. Switch to leflunomide in combination with methotrexate despite current alanine aminotransferase elevation, and reassess in 6 months**\nThe combination of methotrexate and leflunomide is generally avoided due to a synergistic and high risk of hepatotoxicity. Initiating this combination in a patient who already has elevated ALT from methotrexate would be extremely hazardous.\n**Verdict: Incorrect**. This combination poses an unacceptably high risk of liver damage.\n\n**F. Initiate a Janus Kinase (JAK) inhibitor (for example, tofacitinib) in view of inadequate response to methotrexate, despite a prior unprovoked deep vein thrombosis**\nJAK inhibitors are an effective class of targeted synthetic DMARDs. However, they carry a well-documented, regulatory agency-mandated (e.g., FDA black box) warning for an increased risk of serious thrombotic events, including DVT and pulmonary embolism. Given this patient's history of an unprovoked DVT, initiating a JAK inhibitor would be contraindicated as it would place her at significant risk for a recurrent, potentially fatal, thrombotic event.\n**Verdict: Incorrect**. This option is contraindicated due to the patient's history of DVT.\n\nIn summary, adding a TNF inhibitor (Option B) is the most appropriate next step. It is a highly effective, guideline-concordant strategy for this patient with moderate-to-high activity and poor prognostic features. The necessary safety screen for tuberculosis is negative, and the primary contraindication for another major class of advanced therapy (JAK inhibitors) is present, further strengthening the case for a TNF inhibitor.", "answer": "$$\\boxed{B}$$", "id": "4447046"}]}